All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

News

Article

November 2, 2008

Pharmaceutical Technology

Pharmaceutical Technology-11-02-2008
Volume32
Issue 11

Trends In: FDA Enforcement Actions

Author(s):

Angie Drakulich

During the past five-plus years, the number of US Food and Drug Administration enforcement actions seems to have dropped significantly in the areas of seizures, permanent injunctions, and warning letters (see table). One may question whether the drop means companies are in better compliance these days, or whether FDA's drained resources are preventing the agency from following up every potential violation. Alyson Saben in the Office of Enforcement at FDA's Office of Regulatory Affairs provided some insight into this issue.

FDA Enforcement, FY 2003–FY 2008.

"In many cases, agency enforcement actions are taken for matters that are of greatest public health concern and which will have the greatest impact on consumer protection," she said. "We cannot measure the agency's enforcement success—nor can we measure industry compliance—by counting warning letters and other actions, individually."

These actions represent only a small portion of the "full spectrum of FDA's compliance efforts and the overall impact of those actions on consumer protection," adds Saben. For example, the statistics in the table do not include the accomplishments of FDA's Office of Criminal Investigations (OCI). In fiscal year 2008 (FY 2008), as of Sept. 10, OCI initiated 405 criminal investigations, made 319 arrests, and secured 311 convictions with fines, restitutions, and other monetary penalties totaling more than $153 million.

In addition, FDA's efforts in the import arena have a large impact in the enforcement arena. In 2007, the agency processed approximately 16 million lines of FDA-regulated products contained in import entries. Through the use of administrative actions such as Import Alerts and sampling efforts at the border, numerous, potentially violative, FDA-regulated products of foreign origin were prevented from reaching US consumers. And numerous other FDA "interventions," including inspections, sample collections/analyses, and issuance of 483s, take place daily, explained Saben, which result in corrective actions and consumer protection.

"The agency also seeks to expand the impact of these actions through its communication efforts, thereby achieving a broader, potential deterrent effect industry-wide," says Saben.

Articles in this issue

The Ideal Pharmacopeia
i2-564664-1408652835781.gif
The Role of Dendrimers in Topical Drug Delivery
i2-564659-1408652858920.gif
Nanotechnology Challenges FDA and Manufacturers
i1-564661-1408652852847.jpg
Exploring Solid-State Chemistry
i1-564652-1408652882509.jpg
Bringing Certainties to a Burgeoning Field
i1-564669-1408652812017.jpg
Pharma Capsules
i1-564670-1408652809747.jpg
RFID versus Barcode
Inside USP: USP Metals Testing: A Workshop Report
i4-564657-1408652866899.gif
Report From: China
Report from: India
FDA Collaborates on Nanotechnology Research
i17_t-564663-1408652839813.gif
The Effect of Mill Type on Two Dry-Granulated Placebo Formulations
i1-564668-1408652815465.jpg
Leading European CMOs Consolidate Market Positions
i9_t-564662-1408652847580.gif
Development of Orally Disintegrating Tablets Based on a New Excipient
i12_t-564665-1408652826875.gif
Science and Technology of Bioadhesive-Based Targeted Oral Delivery Systems

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Related Content
Advertisement
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
August 5th 2025

Lilly’s Kisunla Demonstrates Growing Benefit in Treating Early Alzheimer’s Disease

Feliza Mirasol
Findings from a Phase III study highlight the demonstrated action of donanemab-azbt (brand name Kisunla) in slowing the decline of patients exhibiting early symptomatic Alzheimer’s disease.
Drug Solutions Podcast: Growth and Advancements in Fill/Finish
August 5th 2025

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
August 5th 2025

Roche Reveals New Data from Alzheimer’s Disease Research at AAIC 2025

Feliza Mirasol
The company presented new data from its Alzheimer’s disease research efforts across its diagnostics and pharmaceutical portfolios at this year’s AAIC.
Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail
August 5th 2025

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.
Survey with blurred city abstract lights background | Image Credit: © Tierney - stock.adobe.com
August 5th 2025

Survey: Impacts of Tariffs & Trade Policy on the Bio/pharmaceutical Industry

Christopher Cole
Help us get a better picture of how new tariffs and trade policy have impacted you and your organization.
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
August 5th 2025

FDA Changes Opioid Pain Medication Labeling Requirements

Susan Haigney
The changes, required for safety labeling of all opioid drugs, will emphasize the risks with long-term use to combat misuse and addiction.
Related Content
Advertisement
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
August 5th 2025

Lilly’s Kisunla Demonstrates Growing Benefit in Treating Early Alzheimer’s Disease

Feliza Mirasol
Findings from a Phase III study highlight the demonstrated action of donanemab-azbt (brand name Kisunla) in slowing the decline of patients exhibiting early symptomatic Alzheimer’s disease.
Drug Solutions Podcast: Growth and Advancements in Fill/Finish
August 5th 2025

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
August 5th 2025

Roche Reveals New Data from Alzheimer’s Disease Research at AAIC 2025

Feliza Mirasol
The company presented new data from its Alzheimer’s disease research efforts across its diagnostics and pharmaceutical portfolios at this year’s AAIC.
Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail
August 5th 2025

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.
Survey with blurred city abstract lights background | Image Credit: © Tierney - stock.adobe.com
August 5th 2025

Survey: Impacts of Tariffs & Trade Policy on the Bio/pharmaceutical Industry

Christopher Cole
Help us get a better picture of how new tariffs and trade policy have impacted you and your organization.
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
August 5th 2025

FDA Changes Opioid Pain Medication Labeling Requirements

Susan Haigney
The changes, required for safety labeling of all opioid drugs, will emphasize the risks with long-term use to combat misuse and addiction.
About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.